Replies to post #97606 on Quantum Materials Corp. (fka QTMM)

[QuantumTravesty]

Can anyone please help me understand the enthusiasm here for anything test kit related when qmc has three known agreements two awaiting FDA and the MicroGenDX kit which appears to have gone nowhere with only 50-100 downloads on googleplay as anecdotal proof. We know it’s not an international hit as the UK appears to be Innovas largest customer and they’re not using HealthID. Hell HealthID isn’t even up and integrated yet if we are interpreting the loan agreements correctly. Does everything revolve around LinkedIn says there’s 33 people and they borrowed a lot of money mean something good is going to happen to the price of the stock?
Is it tests are using gold and qmc can make gold particles? Tests are using dots and they can make dots?
Somewhere I’ve lost the storyline that connects qmc to revenue I guess.

When every manufacturer seems to be using quantum dots for displays now and qmc used to say they can make dots for displays but aren’t involved in the display supply chain now I must have lost the ability to follow the breadcrumbs.

[TedJ]

"Competition that can ramp up to 50 million test kits a day ?"

The conversation was not about the cheap antigen tests, it was examining the potential for the next generation QD tests that QMC is supposedly developing and when they may bring it to market.

Yes most understand that Innova is distributing large quantities of antigen and maybe antibody tests to a number of countries and that Innova is claiming that they can greatly increase the numbers by bring new production locations on line.

This certainly is good for Innova, Pasaca and Biotime since they have tremendous sales and growth potential.

But some investors are still looking for some confirmation that QMC is actually benefitting from all of these activities. Actual sales or royalties from the HID app, nanoparticles, QDs or blockchain usage.

What I did find interesting in the article that you linked to:

https://www.statnews.com/2021/02/05/a-waste-of-money-the-home-covid-19-test-funded-by-the-biden-administration-is-too-costly-and-complex-critics-say/

was this quote from Michael Mina:

Mina and others said they have concerns about the equity of the Ellume test. It is priced at $30, far too expensive for most Americans to conduct frequent, regular screening at home. And the test is linked to a smartphone app that requires some tech savvy and steps that Mina and others said add difficulty and confusion for most potential users. The test kit transmits results to users via the app, and conveys data to local public health agencies to enable tracking case counts and contacts.

It appears that Mina is not necessarily a big fan of add-on technology to testing.